Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy

(2010) F.- C. Bidard et al.   ANNALS OF ONCOLOGY

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

(2009) N Murukesh et al.   BRITISH JOURNAL OF CANCER

Bevacizumab in the treatment of breast cancer

(2009) Angelos K. Koutras et al.   CANCER TREATMENT REVIEWS

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

(2009) L. Jain et al.   MOLECULAR CANCER THERAPEUTICS

Influence of theVEGF-A936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer

(2009) Jean-Louis Formento et al.   PHARMACOGENOMICS

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study

(2008) A. Dowlati et al.   CLINICAL CANCER RESEARCH

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

(2008) H. J. Burstein et al.   CLINICAL CANCER RESEARCH

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY